MedTrace Logo

Functional Study of Inhibitory Neurotransmission in the Human Epileptic Brain.

NCT05459090 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2022-08-02

No results posted yet for this study

Summary

Epilepsy is a neurological condition that afflicts 1% of the world population. 30% of patients become drug-resistant to classic antiepileptic treatment and only a small percentage, 5%, can undergo a neurosurgical resection of epileptic focus and recover almost completely from symptoms. To date, an imbalance between inhibitory and excitatory neurotransmission has been well accepted as the main root cause of epilepsy. A better understanding of the molecular mechanisms of this can lead to developing new therapeutic strategies. The investigators of the project want to describe the functional alteration of GABA- A receptor, the main actor of inhibitory neurotransmission in the central nervous system and characterize its subunit composition in the epileptic foci of patients with temporal lobe epilepsy. The authors, also, want to modulate, by means of selective neuroactive molecules, the function of this receptor to increase the inhibitory tone in the epileptic brain.

Conditions

  • Drug Resistant Epilepsy

Interventions

OTHER

ex-vivo study

ex-vivo experiments in tissue slices obtained from biopsies

Sponsors & Collaborators

  • Neuromed IRCCS

    lead OTHER

Principal Investigators

  • katiuscia Martinello, Biology · Neuromed IRCCS

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-29
Primary Completion
2025-02-28
Completion
2027-07-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05459090 on ClinicalTrials.gov